• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk.利妥昔单抗用于具有高免疫风险的原发性膜性肾病患者。
Kidney Int Rep. 2023 May 16;8(8):1660-1664. doi: 10.1016/j.ekir.2023.05.009. eCollection 2023 Aug.
2
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.利妥昔单抗治疗巴基斯坦人群难治性特发性膜性肾病
J Ayub Med Coll Abbottabad. 2019 Apr-Jun;31(2):265-268.
3
The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.利妥昔单抗治疗膜性肾病的疗效。
J Nepal Health Res Counc. 2021 Jan 21;18(4):580-587. doi: 10.33314/jnhrc.v18i4.2481.
4
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.每月小剂量利妥昔单抗治疗原发性抗 PLA2R 阳性膜性肾病：一种个体化方法。
BMC Nephrol. 2023 May 26;24(1):146. doi: 10.1186/s12882-023-03206-1.
5
[Membranous nephropathy: New insights in therapeutic approach].[膜性肾病：治疗方法的新见解]
Nephrol Ther. 2017 Apr;13 Suppl 1:S83-S87. doi: 10.1016/j.nephro.2017.02.002.
6
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.高剂量利妥昔单抗治疗 PLA2R1 相关膜性肾病的早期缓解作用。
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182. doi: 10.2215/CJN.11791018. Epub 2019 Jul 24.
7
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.利妥昔单抗、低剂量环磷酰胺和泼尼松联合治疗特发性膜性肾病：病例系列
BMC Nephrol. 2017 Feb 1;18(1):44. doi: 10.1186/s12882-017-0459-z.
8
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.STARMEN 试验表明，在原发性膜性肾病中，与他克莫司和利妥昔单抗序贯治疗相比，皮质类固醇和环磷酰胺交替治疗更具优势。
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.
9
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.利妥昔单抗免疫监测预测膜性肾病缓解。
Front Immunol. 2021 Oct 13;12:738788. doi: 10.3389/fimmu.2021.738788. eCollection 2021.
10
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.利妥昔单抗诱导的抗 PLA2R 自身抗体耗竭可预测膜性肾病的反应。
J Am Soc Nephrol. 2011 Aug;22(8):1543-50. doi: 10.1681/ASN.2010111125. Epub 2011 Jul 22.

引用本文的文献

1
Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study.不同年龄的磷脂酶A2受体相关膜性肾病患者的利妥昔单抗治疗：一项单中心回顾性队列研究
Ren Fail. 2025 Dec;47(1):2555688. doi: 10.1080/0886022X.2025.2555688. Epub 2025 Sep 7.
2
Ten tips on immunosuppression in primary membranous nephropathy.原发性膜性肾病免疫抑制治疗的十条建议。
Clin Kidney J. 2024 Apr 29;17(6):sfae129. doi: 10.1093/ckj/sfae129. eCollection 2024 Jun.

本文引用的文献

1
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
2
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.利妥昔单抗或环磷酰胺治疗膜性肾病：RI-CYCLO随机试验
J Am Soc Nephrol. 2021 Apr;32(4):972-982. doi: 10.1681/ASN.2020071091. Epub 2021 Mar 1.
3
Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.利妥昔单抗对伴有抗磷脂酶A2受体抗体滴度持续升高的膜性肾病进行再治疗。
Kidney Int. 2019 Jan;95(1):233-234. doi: 10.1016/j.kint.2018.08.045.
4
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.磷脂酶A2受体（PLA2R）抗体相关膜性肾病的免疫缓解：环磷酰胺与利妥昔单抗对比
Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019.
5
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.利妥昔单抗与类固醇及环磷酰胺治疗特发性膜性肾病的安全性比较
J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.
6
Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.通过检测抗PLA2R抗体并结合检测膜性肾病中PLA2R抗原所发现的PLA2R自身免疫的预后价值：一项为期14年的单中心研究
PLoS One. 2017 Mar 3;12(3):e0173201. doi: 10.1371/journal.pone.0173201. eCollection 2017.
7
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.抗磷脂酶A2受体抗体滴度可预测利妥昔单抗治疗后膜性肾病的疗效。
J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.
8
Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.磷脂酶 A2 受体自身抗体与原发性膜性肾病患者的临床结局。
J Am Soc Nephrol. 2014 Jun;25(6):1357-66. doi: 10.1681/ASN.2013040430. Epub 2014 Mar 7.
9
Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.抗磷脂酶 A2 受体抗体滴度及其亚类在特发性膜性肾病中的变化。
J Am Soc Nephrol. 2012 Oct;23(10):1735-43. doi: 10.1681/ASN.2012030242. Epub 2012 Sep 6.

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk.

作者信息

Naik Sachin, Pal Deeksha, Shukla Shubham, Kumar Vinod, Kumar Ashwini, Jha Vivekanand, Minz Ranjana, Sethi Jasmine, Bharati Joyita, Divyaveer Smita, Kumar Vivek, Rathi Manish, Kohli Harbir Singh, Ramachandran Raja

机构信息

Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Department of Dermatology, Venereology and Leprosy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

Kidney Int Rep. 2023 May 16;8(8):1660-1664. doi: 10.1016/j.ekir.2023.05.009. eCollection 2023 Aug.

DOI:10.1016/j.ekir.2023.05.009
PMID:37547518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10403650/
Abstract
摘要